Matrai Gyogyintezet — Clinical Trial Site

34 Registered trials

18 Currently recruiting

Organisation

Matrai Gyogyintezet

Location

Gyongyos, Hungary

Identifier

ORG-100041516

Address

Matrahaza Hrsz 7151, 3200, Hungary

Departments

-
4701: NA
Bronchologia
Bronchologiai Osztaly
Bronchology Department
Department of Bronchology
III Pulmonológia
III. Pulmonológia
n/a
NA
Oncológiai
Onkologiai szakrendeles
Pulmonologia Osztaly
Pulmonológiai Osztály
Pulmonology
Pulmonology Department

Clinical trials at this site (34)

Search interface

A Study of Dato-DXd in Combination With Durvalumab and Carboplatin for First-line Treatment of Advanced NSCLC Without Actionable Genomic Alt… Ended

2023-505993-14-00 Non-Small Cell Lung Cancer (NSCLC) 5 2023-01-05
PH2a, Platform Study of Novel Immunotherapy Combinations in Participants with Previously Untreated, Advanced/Metastatic NSCLC Ended

2023-505057-40-00 Lung Cancer, Non-Small Cell 4 2022-12-02
A Study of Durvalumab Before and After Surgery for Patients with Operable Non-Small Cell Lung Cancer. Ended

2023-509576-42-00 Patients with resectable Non-small Cell Lung Cancer (St 5 2019-02-21
A global study of volrustomig (MEDI5752) plus chemotherapy versus pembrolizumab plus chemotherapy for participants with metastatic non-small… Halted

2023-503298-39-00 Metastatic Non-Small Cell Lung Cancer (mNSCLC) 5 2024-06-13
Study of efficacy and safety of JDQ443 single-agent as first-line treatment for patients with locally advanced or metastatic KRAS G12C- muta… Halted

2024-511708-18-00 Locally advanced or metastatic KRAS G12C-mutated non-sm 4 2022-12-06
A Study designed to evaluate the efficacy and safety of tiragolumab plus atezolizumab compared with placebo plus atezolizumab administered i… Ended

2023-506696-10-00 Non-Small Cell Lung Cancer 5 2024-06-18
A Study to Investigate MBS2320 Patients with IPF Ended

2023-504418-30-00 Idiopathic Pulmonary Fibrosis 4 2023-10-24
A study of MK7684A versus Pembrolizumab in PD-L1 Positive Metastatic NSCLC (KEYVIBE-003) Ended

2023-505362-28-00 Stage IV non small-cell lung cancer 5 2021-04-21
Placebo-controlled Study Comparing Niraparib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab as Maintenance Therapy in Participants wit… Ended

2023-508443-40-00 Lung Cancer, Non-Small Cell 5 2020-12-18
A Study of Tiragolumab, an Anti-TIGIT Antibody, in Combination with Atezolizumab Compared with Placebo in Combination with Atezolizumab (an … Ended

2022-502482-17-00 Non-small cell lung cancer (NSCLC) 5 2020-05-19